Overview

Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's hydrochlorothiazide 50 mg tablets to Ivax's Hydrochlorothiazide 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.
Phase:
Early Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Hydrochlorothiazide